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Abstract 58 
 59 
The nature of basophil activation as an ex vivo challenge makes it a multifaceted and promising 60 
tool for the allergist. Through development of flow cytometry, discovery of activation markers such 61 
as CD63 and markers identifying basophil granulocytes the basophil activation test (BAT) has 62 
become a pervasive test. BAT measures basophil response to allergen crosslinking IgE on between 63 
150 and 2000 basophil granulocytes with remarkable analytical sensitivity in less than 0.1 ml fresh 64 
blood. Dichotomous activation is assessed as the fraction of reacting basophils. In patients with 65 
food-, insect venom-, and drug allergy as well as with  chronic urticaria BAT can be part of the 66 
diagnostic evaluation in addition to history, skin prick testing and specific IgE determination.  BAT 67 
may be also helpful in determining the clinically relevant allergen. Basophil sensitivity may be used 68 
to monitor patients on allergen immunotherapy, anti-IgE treatment or in the natural resolution of 69 
allergy. The test may use fewer resources and be more reproducible than oral, sting, nasal or 70 
bronchial challenge testing. BAT may be useful before challenge testing as it is less stressful for the 71 
patient and avoids severe allergic reactions. An important prospective step is to standardize BAT 72 
and make it available in diagnostic laboratories.  73 
 74 
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Introduction 95 
 96 
The clinical impact of BAT is due to the unique ability of basophils to degranulate upon cross-97 
linking of the specific IgE (sIgE) bound on membrane-bound high affinity IgE-receptor (FcεRI) by 98 
allergen exposure. After discovery of the quantal upregulation of CD63 during basophil activation 99 
in 1991(1), the BAT was developed in the 90’s (2).  CD63 is a membrane protein localized to the 100 
same secretory lysosomal granule that contains histamine. Translocation of CD63 to the cell 101 
membrane during degranulation can be measured by flow cytometry. BAT (like SPT) reflects a 102 
functional response as basophil (or skin mast cell) activation can be induced by cross-linking of 103 
FcεRI.  104 
In this overview, adapted from the EAACI Task force position paper (3) we provide an overview of 105 
the practical and technical details as well as the utility of BAT in diagnosis and management of 106 
allergic diseases.  107 
 108 
Blood samples for BAT  109 
 110 
Antihistamines do not interfere with BAT, but systemic steroids and cyclosporin A should be 111 
avoided (4,5). It is recommended to take blood samples within one year of the most recent exposure 112 
to the allergen source (6,7). Blood samples can be used within 24 hours (8), even though basophils 113 
may lose reactivity. As there is diurnal variation in the reactivity to CD203c (9), timing of blood 114 
sampling may be important. Tests done with whole blood are most commonly utilized, but 115 
separation of cells from protective elements found in plasma may optimize activation through cell-116 
bound sIgE. 117 
Interleukin-3 (IL-3) enhanced kinetics, reactance and sensitivity of blood basophils to FceRI 118 
mediated activation independently of extracellular Calcium. It enhances also the allergen specific 119 
up-regulation of CD63 (4,10), but unspecifically upregulates CD203c (11).  120 
 121 
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Selection of the source of allergen extracts (Box 1)                                                    122 
Optimized concentrations for a wide range of allergens, allergen sources and allergen extracts 123 
are listed in the original position paper in table S1 (3). Furthermore, optimized allergen 124 
preparations are available from vendors. Drug allergens are typically active in the mg/ml range, 125 
and can be diluted 5- to 25-fold. Pure active ingredients or injectable intravenous drug preparations 126 
should be used when possible since solubilized tablets are complex mixtures of drugs and 127 
excipients.  128 
Protein allergens are often used in concentrations starting in the µg/mL range, and may be diluted 129 
up to 5 – 15 log concentrations to ng/ml - pg/ml before reactivity is lost. If recombinant allergen 130 
preparation or purified allergens are used for BAT, the molar concentration of allergens enables 131 
very precise analyses.  132 
This standardized allergen preparation is essential when comparing basophil sensitivity data.  133 
Flow Cytometry in BAT 134 
 135 
At the moment BAT with CD63 is the best clinically validated test (,12,13,14), but the BAT 136 
based on CD203c has been shown to be a reliable test (15,16).  137 
Basophils can be identified with different combinations of antibodies in flow cytometry. They 138 
were first identified as circulating IgE+ cells. However, low side scatter in combination with 139 
CD123+/HLADR-, CRTH2+, CD203c+ or CD193+ are commonly applied combinations. Cell 140 
surface expression of the basophil selection marker CD193 (CCR3) was more stable than IgE 141 
or CD123/HLA DR on resting basophils (17). IgE and CD123/HLA-DR showed somewhat 142 
more inter-individual variability in cell surface expression. CD203c can be used for both 143 
identification and as an activation marker. Quality of blood basophils obtained is usually 144 
confirmed by stimulation with the bacterial peptide fMLP. Anti-IgE or anti-FcεRI antibodies 145 
are used as IgE-mediated positive controls, buffer as negative control.  146 
If standardized commercial tests are not used, the method used for testing has to undergo 147 
validation.  148 
 149 
Presentation and interpretation of BAT 150 
There are two common measures of basophil activity; basophil reactivity (2), the number of 151 
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basophils that respond to a given stimulus, and basophil sensitivity (1, 18), the allergen 152 
concentration at which half of all reactive basophils respond (Fig. 1A). Basophil reactivity 153 
depends on the priming state of the basophil and the cellular translation of the IgE signal 154 
within the cell (19). It is sufficient to measure reactivity at one or two concentrations, and 155 
assessment of basophil reactivity is important using a positive control before basophil 156 
sensitivity to allergen is measured.   157 
Basophil sensitivity is a function of reactivity and the compound affinity of cell-bound sIgE for 158 
allergen and free competing immunoglobulin. It requires measurement of reactivity at 6-8 159 
allergen concentrations. The graded response to allergen is fitted to a curve of reactivity 160 
versus allergen concentration, and the eliciting concentration at which 50% of basophils 161 
respond (EC50) is determined (Fig. 1 B). EC50 can be expressed as ‘CD-sens’ by inversion and 162 
multiplication by 100 (20).  163 
More recently the area-under-the-dose curve (AUC) measurement attempts to combine 164 
reactivity and sensitivity into one (Fig. 1C); it is similar to a coordinate system of sensitivity 165 
and reactivity, but also incorporates partial anergy induced at high allergen concentrations 166 
and can be calculated even in cases where responses do not fit well to a typical dose-response 167 
curve (21). ROC curves are used in identification of novel allergens when ≥7 sensitized 168 
patients are available.  169 
Basophil granulocytes of non-responders (6%-17% of population) can remain unresponsive 170 
to stimulation through FcRI. It is attributed to differences in the intracellular signaling 171 
pathway. Results from non-responder patients should be regarded as false negatives.  172 
 173 
Placing BAT in the diagnostic algorithm for allergic disease 174 
In the general algorithm for diagnosis of allergy (Box 2), patient history should be taken with 175 
an attempt to identify the allergen source and assess the severity of the allergic reaction. The 176 
allergic response should be confirmed by measurement of sIgE, skin prick testing and, for 177 
insect venom and drug allergy, intradermal testing. Measurement of sIgE may not be possible 178 
if the allergen source is not available as a routine reagent, and may be of limited value 179 
depending on the performance of the available reagents. BAT is a functional test resembling 180 
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an ex vivo IgE-mediated cellular response . It can be measured at the same time as sIgE, and in 181 
general precedes in vivo provocation tests.  182 
 183 
Chronic Urticaria 184 
The mechanism of chronic spontaneous urticaria (CU) is still incompletely understood. About half 185 
of the patients have autoantibodies against FcεRI and a few against IgE. CU sera activate resting 186 
basophils of normal donors to upregulate CD63 and CD203c. BAT may replace the autologous 187 
serum skin test (ASST) (22).  188 
BAT with CD63 upregulation as an activation marker for CU was established as a specific, 189 
sensitive and safe in vitro alternative to detect functional autoantibodies (10,  23, 24). The central 190 
problem is the heterogeneity of the results using different basophil donors. This can be normalized 191 
by titrated addition of IL-3 (10). BAT with autologous basophils should not be performed because 192 
CU patients are often non responders or poor responders to IgE crosslinking and have diagnostic 193 
basopenia.   194 
Key messages 195 
 BAT may replace ASST as the standard diagnostic procedure to identify autoreactive serum 196 
factors in CU with a quantifiable result that may be used to monitor treatment.  197 
 BAT removes the risk of accidental infection. 198 
 In contrast to ASST, there is no need to suspend antihistamines, as they do not influence the 199 
result of BAT. 200 
 201 
Drug Allergy  202 
The diagnostic work-up of drug hypersensitivity reactions (DHR) aims to identify the culprit agent, 203 
identify cross-reactive drugs and to determine a safe alternative drug (25). Here BAT is an 204 
additional tool that is safer, gentler and cheaper than a challenge and, in some instances, is the only 205 
available diagnostic tool. The sensitivity of BAT in diagnosis of drug allergy is about 50%, and the 206 
specificity up to 93%.  207 
There are several studies including BAT in drug allergy diagnosis for beta-lactams, NMBA, 208 
quinolones, radio contrast media and pyrazolones with good sensitivity and specificity. 209 
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BAT provides positive results in 40% of the patients with immediate-type systemic reaction and 210 
negative skin test and confirmed by provocation that constitute about 25% of all beta-lactam-211 
allergic patients. BAT has also a good negative predictive value, useful in the decision to perform 212 
the provocation test as demonstrated with quinolones. Furthermore, it has a complementary role to 213 
skin tests for different drug hypersensitivities and can be particularly useful in the study of cross-214 
reactivity between NMBA, for the identification of safe alternatives for future surgery ( 25, 26).  215 
. 216 
Key Messages 217 
 For a number of drugs, BAT is the only available test to confirm a hypersensitivity response. 218 
 A negative test does not rule out that the patient reacts to a metabolite of the drug. 219 
 It may be difficult to confirm the clinical history of hypersensitivity by BAT after 18 months 220 
from the most recent clinical reaction. 221 
 Once the hypersensitivity is established, cross-reacting drugs and safe alternatives may be 222 
suggested by BAT.  223 
 224 
 225 
Food allergy  226 
The performance of BAT in the diagnosis of food allergies has been assessed in various studies. 227 
The reported sensitivity of BAT ranges from 77-98%, and the specificity from 75-100%. BAT in 228 
these studies was more accurate than sSPT and sIgE ( 27, 28). For single individuals BAT 229 
sensitivity seems to allow a risk estimation for severe clinical reactions: In peanut allergy, BAT 230 
significantly improved clinical diagnosis over the use of SPT and sIgE and reduced the number of 231 
OFC required. BAT showed 100% specificity, suggesting that in patients with a positive BAT the 232 
OFC could be deferred (29). 233 
Patients with clinical allergy that developed symptoms in an OFC to peanut had high basophil 234 
sensitivity to peanut, and patients who tolerated peanuts in a OFC had low basophil sensitivity to 235 
peanut. Although OFC and basophil sensitivity both identified all clinically sensitized children, 236 
only basophil sensitivity was reproducible at two consecutive visits (r2=0.94). In a recent 237 
publication, BAT reactivity reflected the allergy severity and BAT sensitivity reflected the 238 
threshold of response to the allergen source in an OFC (30). 239 
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 240 
It has been shown that basophil reactivity distinguish patients that tolerate extensively heated forms 241 
of cow’s milk and egg from patients who do not. BAT may be useful in assessing the natural 242 
resolution of food allergies that are commonly outgrown over time, such as cow's milk allergy (28), 243 
and in determining when the food can safely be reintroduced in the diet. BAT has also been used to 244 
monitor clinical response to immune-modulatory treatment of food allergy.  245 
Basophil CD203c expression has shown to decrease during treatment with Omalizumab and to 246 
return to pre-treatment levels after cessation of therapy in patients with peanut allergy (31). Also 247 
improvement in basophil sensitivity to milk of milk allergic children treated with Omalizumab 248 
predicted tolerance in a milk challenge test. 249 
 250 
 251 
Key messages 252 
 BAT can improve the diagnosis of food allergy in addition to  SPT and sIgE and may be 253 
able to reduce the number of OFC. 254 
 BAT can be used to monitor the natural resolution and clinical response to immune- 255 
modulatory treatments for food allergy.  256 
257 
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Hymenoptera venom allergy  258 
Overall, the diagnostic sensitivity of BAT with insect venoms referred to the history was found to 259 
be 85%-100%, the diagnostic specificity 83%-100% (13,14,15). Specific diagnostic problems can 260 
be resolved by measuring basophil reactivity and sensitivity. 261 
BAT in patients with negative standard tests: A subset of patients (4-6%) with a history of systemic 262 
reactions after Hymenoptera stings have negative venom-specific IgE and skin test results. BAT 263 
allows the identification of about two thirds of those patients (32).  264 
BAT in patients sensitized to bee and wasp venom “double positivity”: Up to 60% of the patients 265 
with Hymenoptera venom allergy have sIgE to both bee and wasp venom. Basophil reactivity has 266 
the lowest rate of double positivity of diagnostic tests for hymenoptera allergy (33) and repeatedly 267 
shows a positive result to only one venom in about one-quarter to one-third of patients with double 268 
sIgE positivity (13 34). In the case of patients with double positive BAT, the venomto which the 269 
patient is markedly more sensitive might represent the primary sensitizing allergen source, but this 270 
requires further research. BAT adds more clinically relevant information about the culprit insect 271 
than component-resolved sIgE testing with single recombinant allergens (32, 34). However, 272 
recombinant venom allergens applied to BAT might represent a step forward in developing better in 273 
vitro tests for specific diagnosis of Hymenoptera allergy. 274 
Monitoring the effect of venom immunotherapy with basophil sensitivity: A clear decrease in 275 
basophil sensitivity is found up to 4 years after initiation of VIT, without a change in basophil 276 
reactivity. A recent report about an 8-year follow up of patients submitted to VIT showed that the 277 
decrease in basophil sensitivity seemed to be also associated with the induction of tolerance (35). 278 
Some studies suggest that side effects during the build-up phase of VIT are predicted by a high 279 
basophil sensitivity (36).  280 
Key messages 281 
 Basophil reactivity and sensitivity (in that order) play an important role in the diagnosis of 282 
venom allergy, as they are effective tools to identify the primary sensitizing antigen.  283 
 The utility of basophil sensitivity as the tool of choice to monitor the effect of VIT should be 284 
explored. 285 
  286 
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Inhalant allergens 287 
Determination of sIgE or skin testing in combination with the clinical history are usually sufficient 288 
to diagnose allergy to inhalant allergens. However, in specific cases BAT can be helpful for 289 
diagnosis. Patients with local allergic rhinitis by nasal provocation who have no detectable sIgE or 290 
skin testing but have a positive BAT are a notable example (37). Crude allergen sources as well as 291 
modified and recombinant allergens have been tested with good outcomes, Basophil sensitivity 292 
correlates with the nasal provocation titer in allergic rhinitis (38), the allergen specific bronchial 293 
provocation threshold in allergic asthma and the asthma control test. This indicates that basophil 294 
allergen threshold sensitivity (CD-sens or EC50) may accurately reflect clinical allergen sensitivity 295 
(39).  296 
Monitoring the effect of allergen immunotherapy and anti-IgE treatment effect: Basophil 297 
sensitivity can be used to assess the efficacy of allergen-specific immunotherapy (AIT) to 298 
aeroallergens. It has been used to monitor patients treated with AIT for birch and timothy (18,19), 299 
and showed reduced allergen sensitivity already during the up-dosing stage. Basophil sensitivity has 300 
also successfully been used to identify patients who respond to the humanized monoclonal anti-IgE 301 
antibody Omalizumab and to assess treatment efficacy (40). 302 
Key message 303 
 Basophil sensitivity has the unique ability to monitor a patient’s inhalant allergen sensitivity 304 
over time, to measure natural progression of allergy, and may be developed to serve as a 305 
tool to measure the response to treatment with AIT and Omalizumab. 306 
 307 
Perspectives 308 
Different methods of reporting results of BAT may be useful when asking different clinical 309 
questions; stimulation index and % positive basophils are used. When reactivity is measured in 310 
clinical settings, the aim is usually to identify an allergen concentration at which change in 311 
sensitivity is optimally identified. Basophil sensitivity is used to monitor change in allergic disease. 312 
Both reactivity and allergen sensitivity are measured when allergy severity is evaluated by basophil 313 
sensitivity, but a useful composite measure has yet to be designed.  314 
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A threshold for basophil reactivity is often set at 2%, 10% or 15% of resting basophils. An 315 
alternative method would be to set the threshold halfway between the MFI of resting basophils and 316 
the positive control.  317 
Major applications of BAT are summarized in Box 4. Laboratory procedures and allergen 318 
concentrations in BAT should be standardized e.g by the use of industry standards like MiFlowCyt 319 
or purchase of standardized material from CE-approved vendors. An important next step is the 320 
standardization and automation of analysis of BAT.  Then it will be possible to perform  large 321 
multicenter trials to characterize the diagnostic performance of BAT and broaden its use as a 322 
clinical tool. Such studies should also address the relationship of measures of BAT and sensitivity 323 
to sIgE, clinical symptoms and symptom severity. 324 
 325 
 326 
 327 
 328 
 329 
 330 
 331 
 332 
 333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
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Figure 1: Assessing basophil response.  514 
The fraction of CD63+ basophils is plotted against log allergen concentration. Adapted from 515 
(20) with permission from the authors. 516 
A. Basophil reactivity is the dose (range) at which maximal response occurs. Basophil 517 
sensitivity is the dose at which half of the maximal response occurs. *At high allergen 518 
concentrations, basophil response may be suppressed.  519 
B. A change in sensitivity toward higher allergen concentration is the most reproducible 520 
basophil biomarker for reduced clinical sensitivity to allergen to date. Attempts to reduce the 521 
number of BAT tests required to determine a significant change in basophil response have 522 
focussed on identifying an allergen concentration at which a change in sensitivity can readily 523 
be assessed (grey box). 524 
C. Basophil response could also be assessed as area under the curve (AUC) with a log allergen 525 
axis, or a similar composite measure reflecting both reactivity and sensitivity. Variation in 526 
maximal basophil reactivity arises concurrently with, and may be inseparable from, a change 527 
in sensitivity.  528 
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